Prevention of Ocular Scarring Post Glaucoma Filtration Surgery Using the Inflammatory Cell and Platelet Binding Modulator Saratin in a Rabbit Model

Min, Jin Sik; Lukowski, Zachary; Levine, Monica A.; Meyers, Craig; Beattie, Ashley R.; Schultz, Gregory S.; Samuelson, Don; Sherwood, Mark B.

doi:10.1371/journal.pone.0035627

Cited by 24 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recombinant Saratin was obtained in yeasts (Hansenula polymorpha) [104] and it is being commercialized by BioVascular which has developed this product to GMP standards and is evaluating the effects in clinical studies [105]. To date, in the literature, only a few animal studies have been published, where it has been given alone or together with other drugs in glaucoma rabbit models [106,107]. Saratin, when administrated alone in rat carotid endarterectomy model, significantly decreased platelet adhesion, intimal hyperplasia, luminal stenosis, and thrombosis.…”

Section: Other Inhibitors Of Factor Xamentioning

confidence: 99%

Anticoagulants from Hematophagous

Chudzinski-Tavassi¹,

Faria²,

Flores³

2018

Anticoagulant Drugs

View full text Add to dashboard Cite

This chapter will focus on anticoagulant molecules described until now from hematophagous animals. The evolutionary scenario for hematophagous animals is convergent and has resulted on a wide diversity of saliva anticoagulants, substances with platelet antiaggregation action, and also with vase-dilating action. Hematophagous animals such as bloodsuckers (leeches, mosquitoes, and ticks) have developed strategies that specifically target proteinases from the hemostatic system of the animals they feed, thus keeping the blood incoagulable. The saliva of those animals provides a large amount of molecules to modulate the innate immune response of the host and to inhibit blood coagulation in order to facilitate the feeding. Thus, anticoagulants from hematophagous animals represent a very interesting tool for studies ranging from basic research to applications in the therapeutic area, as anticoagulant medication. Several studies have pointed out that anticoagulants from hematophagous can also display non-hemostatic functions as antitumor, bringing new perspectives for the study of these molecules. The comprehension of the multi-faced physiological roles of those new anticoagulants from hematophagous opens new perspectives for therapeutic and biotechnological approaches.

show abstract

Section: Other Inhibitors Of Factor Xamentioning

confidence: 99%

Anticoagulants from Hematophagous

Chudzinski-Tavassi¹,

Faria²,

Flores³

2018

Anticoagulant Drugs

View full text Add to dashboard Cite

show abstract

“…It is also noted that results from an animal study may not be directly applicable to human patients. The New Zealand rabbit is, however, an established model for evaluation of glaucoma surgery [10,17,18,26]. Fig.…”

Section: Discussionmentioning

confidence: 99%

“…Inhibition of TGF-b showed promise in animal models, but a clinical study found that a monoclonal antibody (CAT-152) was not effective at preventing trabeculectomy failure [13]. Preliminary studies investigating anti-transforming growth factor b2 (anti-TGF-b2), anti-vascular endothelial growth factor (anti-VEGF), anti-placental growth factor (anti-PIGF), inhibitors of platelet collagen interaction (saratin), and application of amniotic membrane have all shown success, but have not expanded to clinical trials [14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Effect of Novel Design Modifications on Fibrotic Encapsulation: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model

et al. 2020

View full text Add to dashboard Cite

Purpose: To quantify the effects of modified Ahmed glaucoma valves Ò (AGV) with anti-fibrotic plate coatings or a plate surface micropattern on outflow resistance and tissue response. Methods: Twelve New Zealand rabbits were divided into four groups: commercially available AGV implants (n = 3), AGV with hydrophilic coating (n = 3), AGV with heparin coating (n = 3), and AGV with a plate surface micro-pattern (n = 3). After 6 weeks, the anterior chamber silicone tube was cannulated in situ and perfused with 2.5 lL/min of saline. The pressures were recorded with a perfusion system to measure outflow resistance. The rabbits were then euthanized followed by enucleation of all eyes for bleb histological analyses. Results: Hydrostatic pressures were significantly lower in AGVs with the hydrophilic plate coating (mean difference-9.6 mm Hg; p \ 0.001), heparin-coated plates (mean difference-4.4 mm Hg; p \ 0.001), and micro-patterned plates (mean difference-18.6 mm Hg, p \ 0.001), indicating lower outflow resistance compared to control AGV models. Fibrotic encapsulation was lower in hydrophilic plate coating (84.2 lm; mean difference-6.2 lm, p = 0.425), micro-patterned surface (63.7 lm; mean difference-26.7 lm, p = 0.003), and heparin plate coating (49.3 lm; mean difference-41.1 lm, p = 0.006) when compared to control AGV models. Conclusions: Modified AGVs with plate coatings and AGVs with micro-patterned plates both appear to reduce postoperative fibrotic encapsulation and aqueous outflow resistance by altering the tissue response to implanted materials. Further studies are needed to characterize the safety and role of plate surface modifications on glaucoma drainage devices.

show abstract

“…Other reports indicated survival rate ranged from 0% to 50% at various follow-up periods (from 4-6 weeks). 16,[37][38][39] From these results, it appears to be difficult to achieve greater than 90% bleb survival (human 1-year goal) at 3 months in a rabbit model of filtration surgery with MMC, because the wound healing reaction is more aggressive in rabbits than in humans. Accordingly, the results of experiment 2 indicate that a HPF with 0.5 lg PTX provided sustained IOP reduction and favorable bleb survival even after a long follow-up period.…”

Section: Discussionmentioning

confidence: 99%